Has Scout24 SE's (ETR:G24) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
Most readers would already be aware that Scout24's (ETR:G24) stock increased significantly by 12% over the past month. As most would know, fundamentals are what usually guide market price movements over the long-term, so we decided to look at the company's key financial indicators today to determine if they have any role to play in the recent price movement. Specifically, we decided to study Scout24's ROE in this article.
Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors' money. Simply put, it is used to assess the profitability of a company in relation to its equity capital.
We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
Return on equity can be calculated by using the formula:
Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity
So, based on the above formula, the ROE for Scout24 is:
11% = €162m ÷ €1.4b (Based on the trailing twelve months to December 2024).
The 'return' is the yearly profit. One way to conceptualize this is that for each €1 of shareholders' capital it has, the company made €0.11 in profit.
View our latest analysis for Scout24
So far, we've learned that ROE is a measure of a company's profitability. We now need to evaluate how much profit the company reinvests or "retains" for future growth which then gives us an idea about the growth potential of the company. Generally speaking, other things being equal, firms with a high return on equity and profit retention, have a higher growth rate than firms that don't share these attributes.
To begin with, Scout24 seems to have a respectable ROE. Even so, when compared with the average industry ROE of 16%, we aren't very excited. Although, we can see that Scout24 saw a modest net income growth of 19% over the past five years. Therefore, the growth in earnings could probably have been caused by other variables. For example, it is possible that the company's management has made some good strategic decisions, or that the company has a low payout ratio. However, not to forget, the company does have a decent ROE to begin with, just that it is lower than the industry average. So this also provides some context to the earnings growth seen by the company.
As a next step, we compared Scout24's net income growth with the industry and found that the company has a similar growth figure when compared with the industry average growth rate of 19% in the same period.
Earnings growth is an important metric to consider when valuing a stock. It's important for an investor to know whether the market has priced in the company's expected earnings growth (or decline). This then helps them determine if the stock is placed for a bright or bleak future. What is G24 worth today? The intrinsic value infographic in our free research report helps visualize whether G24 is currently mispriced by the market.
The high three-year median payout ratio of 53% (or a retention ratio of 47%) for Scout24 suggests that the company's growth wasn't really hampered despite it returning most of its income to its shareholders.
Moreover, Scout24 is determined to keep sharing its profits with shareholders which we infer from its long history of eight years of paying a dividend. Upon studying the latest analysts' consensus data, we found that the company is expected to keep paying out approximately 43% of its profits over the next three years. Still, forecasts suggest that Scout24's future ROE will rise to 18% even though the the company's payout ratio is not expected to change by much.
Overall, we feel that Scout24 certainly does have some positive factors to consider. Specifically, its respectable ROE which likely led to the considerable growth in earnings. Yet, the company is retaining a small portion of its profits. Which means that the company has been able to grow its earnings in spite of it, so that's not too bad. The latest industry analyst forecasts show that the company is expected to maintain its current growth rate. To know more about the latest analysts predictions for the company, check out this visualization of analyst forecasts for the company.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Daily Mail
19 minutes ago
- Daily Mail
Reality star panics after gaining 20lbs when weight loss drug stopped working
The use of weight loss drugs like Ozempic and Wegovy has surged in recent years. But the medications are not foolproof, as evidenced by a reality television star who just revealed hers 'stopped working.' Dolores Catania, 54, appeared on the June 6 episode of Jeff Lewis' eponymous SiriusXM show, where she revealed she's gained 20lbs. 'I'm having a really hard time right now. My Mounjaro stopped working. I gained 20 lbs,' the Real Housewives of New Jersey personality shared. 'I've been looking for therapy for all my friends. I'm really having a bad time with this,' she said while on the show with co-star Margaret Josephs. GLP-1 prescriptions are FDA-approved and are often prescribed to people with diabetes. Mounjaro's main component is tirzepatide, while Ozempic and Wegovy are brand names for semaglutide. The drugs improve satiety, reducing appetite and optimizing how the body processes sugar and fat, according to MayoClinic. Catania initially dropped weight using the medication, but has now gained it back. When asked if switching her medicine could be helpful, she replied, 'I did it all.' She explained that she's no longer taking Mounjaro due to having a cardiac ablation to correct her abnormal heart rhythm. The Bravo star said she's doing 'fine' now: 'I'm on a bunch of medicine, like, 10 pills a day. It's just a formality now. I have to take it for the next 90 days, then I should be done.' And she added, 'Maybe that's why I gained weight. I'm hoping maybe that's why.' Catania was among the first crop of celebrities who openly admitted to using one of the three popular weight loss drugs. After two years of taking it, she said in a February Hello! magazine interview: 'I know it's time for me to wean myself off or go on a lower dose.' Catania weighed 157lbs when she started taking the GLP-1 medication, starting with Ozempic before switching to Mounjaro. She cautioned that anyone considering the medications 'must always go through a real doctor, who knows what they are doing.' 'Research is everything,' she emphasized. The mother-of-two added that the medicine was 'a life changer' for her and boyfriend Paul Connell, who lost 60 pounds. She shared: 'He no longer takes a certain blood pressure medication, and it's been really positive. There are side effects like nausea, but you take a pill for that.' Other stars who have been candid about turning to the weight loss support of Ozempic, Mounjaro, and Wegovy include Amy Schumer, Oprah, and Eric Stonestreet.


New York Post
20 minutes ago
- New York Post
Kirk Cousins sounds resigned to his sad Falcons fate
Kirk Cousins might have already accepted his football fate. Cousins was at the Falcons' mandatory minicamp on Tuesday and seemed to know that his days as a starting quarterback in the NFL might be over. 'Obviously, you'd love to play,' Cousins told reporters. 'But I'm not gonna dwell on things that aren't reality.' Advertisement Cousins, 36, is coming off one of his worst seasons in the league in his 13-year career. He started in 14 games for the Falcons, throwing 18 touchdowns and 16 interceptions with a QBR of 50.4 Advertisement His season came to an end after being benched for rookie quarterback Michael Penix Jr. in week 16, as the Falcons missed out on the playoffs. It's expected that Cousins will become Penix's backup this year, as Atlanta might be left with the 36-year-old quarterback at the start of the 2025 season. Many thought the Falcons would wait until the June 1 deadline to cut the $180 million quarterback, but that deadline has come and gone, and Cousins is still in Atlanta. 3 Kirk Cousins at Falcons minicamp. AP Advertisement That leaves the only option for both parties — a trade. Nevertheless, even that seems less likely with each passing day. 3 Kirk Cousins and Michael Penix Jr. together at Falcons minicamp. AP The Steelers were the last team that desperately needed a quarterback but now have their guy in Aaron Rodgers. Advertisement Cousins said he's not looking at the past and hopes the Falcons have success this year. 3 Kirk Cousins in action at Falcons minicamp. AP 'Certainly there were conversations in January, February, March, even April, but we're moving forward now,' Cousins added. 'Those are things we talked about months ago. Now we need to move forward. Right now, it's about the situation I'm in and being the best I can be and hopefully, in February, we as an organization are holding up the Lombardi Trophy.'
Yahoo
20 minutes ago
- Yahoo
ColonBroom GLP-1 Booster Website Updated to Highlight Daily Supplement for Metabolic Health
New website update showcases natural GLP-1 support supplement designed to curb cravings, support metabolism, and promote healthy weight management SAN FRANCISCO, June 10, 2025 (GLOBE NEWSWIRE) -- ColonBroom, a U.S.-based wellness brand, has announced a new update to its official website to highlight the launch of ColonBroom GLP-1 Booster—a daily supplement formulated to support metabolic function, appetite regulation, and overall weight wellness. Now available across the United States, the product offers a natural, lifestyle-friendly solution backed by science-supported ingredients. According to the official product website ( ColonBroom GLP-1 Booster is designed to work alongside the body's internal systems by promoting satiety, curbing cravings, and supporting blood sugar balance. The formula targets key wellness goals like reducing excess visceral fat and helping users manage weight more effectively without relying on restrictive diets or intense routines. 'ColonBroom GLP-1 Booster reflects our mission to simplify wellness with natural tools that align with modern lifestyles,' said a company spokesperson. 'This formula is designed with purpose—combining evidence-backed ingredients for those seeking real metabolic support.' The formulation includes Berberine, Chromium Picolinate, 5-HTP, Saffron Extract, and Bupleurum Root Extract—ingredients selected for their known roles in supporting GLP-1 activity, blood sugar balance, mood regulation, and fat metabolism. ColonBroom confirms that all supplements are manufactured in facilities that adhere to rigorous quality and safety protocols. The brand offers a satisfaction guarantee for new customers and invites visitors to explore ingredient insights, customer FAQs, and personalized quiz recommendations directly on the website. About ColonBroom ColonBroom is a San Francisco-based wellness brand dedicated to creating clean, effective, and easy-to-use daily supplements. With a focus on transparency and science-backed simplicity, ColonBroom empowers adults to take proactive steps toward digestive and metabolic wellness. Product and Contact Information Brand: ColonBroomWebsite: hello@ (Order Support): 1-888-505-0855Mailing Address: 505 Montgomery Street, 10th & 11th Floors, San Francisco, California, 94111, USA Disclaimer This release is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. The statements made about this product have not been evaluated by the Food and Drug Administration. Individual results may vary. Consumers should consult a qualified healthcare provider before beginning any new dietary supplement. CONTACT: Email: hello@ Phone (Order Support): 1-888-505-0855Sign in to access your portfolio